Extendicare Inc. (TSE:EXE – Get Free Report) hit a new 52-week high on Monday . The company traded as high as C$25.26 and last traded at C$24.85, with a volume of 77178 shares trading hands. The stock had previously closed at C$24.55.
Analyst Ratings Changes
A number of analysts recently weighed in on EXE shares. National Bank Financial increased their price target on shares of Extendicare from C$24.50 to C$29.00 and gave the stock an “outperform” rating in a research note on Thursday, February 5th. Canadian Imperial Bank of Commerce increased their target price on shares of Extendicare from C$18.00 to C$22.00 in a research note on Thursday, November 13th. TD Securities boosted their price target on Extendicare from C$15.00 to C$19.00 in a research report on Thursday, November 13th. Cormark upped their price objective on Extendicare from C$25.00 to C$30.00 in a research note on Wednesday, December 3rd. Finally, Canaccord Genuity Group boosted their target price on Extendicare from C$20.00 to C$22.50 in a report on Thursday, December 4th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, Extendicare presently has an average rating of “Buy” and a consensus price target of C$24.50.
Read Our Latest Stock Analysis on EXE
Extendicare Stock Up 3.3%
About Extendicare
Extendicare Inc, operating solely in Canada, is the largest private-sector owner and operator of long-term care (LTC”) homes and one of the largest private-sector providers of publicly funded home health care services.
Featured Articles
- Five stocks we like better than Extendicare
- The gold chart Wall Street is terrified of…
- America’s 1776 happening again
- NEW LAW: Congress Approves Setup For Digital Dollar?
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
Receive News & Ratings for Extendicare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Extendicare and related companies with MarketBeat.com's FREE daily email newsletter.
